- Home
- GH vs CALX Comparison
GH vs CALX Comparison
Compare GH & CALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- CALX
- Stock Information
- Founded
- GH 2011
- CALX 1999
- Country
- GH United States
- CALX United States
- Employees
- GH N/A
- CALX N/A
- Industry
- GH Medical Specialities
- CALX Telecommunications Equipment
- Sector
- GH Health Care
- CALX Consumer Discretionary
- Exchange
- GH Nasdaq
- CALX Nasdaq
- Market Cap
- GH 4.9B
- CALX 4.2B
- IPO Year
- GH 2018
- CALX 2010
- Fundamental
- Price
- GH $65.46
- CALX $59.46
- Analyst Decision
- GH Strong Buy
- CALX Strong Buy
- Analyst Count
- GH 22
- CALX 5
- Target Price
- GH $64.91
- CALX $64.00
- AVG Volume (30 Days)
- GH 2.2M
- CALX 464.3K
- Earning Date
- GH 10-29-2025
- CALX 10-29-2025
- Dividend Yield
- GH N/A
- CALX N/A
- EPS Growth
- GH N/A
- CALX N/A
- EPS
- GH N/A
- CALX N/A
- Revenue
- GH $828,849,000.00
- CALX $869,193,000.00
- Revenue This Year
- GH $28.30
- CALX $17.57
- Revenue Next Year
- GH $22.98
- CALX $10.16
- P/E Ratio
- GH N/A
- CALX N/A
- Revenue Growth
- GH 28.74
- CALX N/A
- 52 Week Low
- GH $20.14
- CALX $28.61
- 52 Week High
- GH $68.23
- CALX $64.30
- Technical
- Relative Strength Index (RSI)
- GH 59.00
- CALX 48.09
- Support Level
- GH $61.00
- CALX $58.11
- Resistance Level
- GH $68.22
- CALX $61.05
- Average True Range (ATR)
- GH 2.50
- CALX 1.62
- MACD
- GH 0.12
- CALX -0.20
- Stochastic Oscillator
- GH 64.47
- CALX 44.85
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About CALX Calix Inc
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.